تحميل
NYSEHealthcareBiotechnology
أحدث البيانات المتاحة
130.9 US$
+4.27 US$ · +3.37%
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
الإغلاق السابق
130.9 US$
+4.27 US$ · +3.37%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 130.9 US$
نطاق 52 أسبوعًا
السعر الحالي 130.9 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
40
مرتفع السعر
المشاعر
58
مختلط
المخاطر
41
مخاطر أعلى من المعتاد
الزخم
70
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
نطاق اليوم
السعر الحالي 130.9 US$
نطاق 52 أسبوعًا
السعر الحالي 130.9 US$
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
162.67 US$
ارتفاع محتمل بنسبة 24.27%سجل الأسعار غير متاح
عالي: 182 US$متوسط: 162.67 US$قليل: 136 US$عينة محدودة من 4 تقييمات
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Russell 2000 ETFIWM73.44 مليون0.09%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Total Stock Market ETFVTI61 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Extended Market ETFVXF22.94 مليون0.02%95.4 مليار USD0.05%235 US$+0.80%
JPMorgan Active Growth ETFJGRO21.64 مليون0.21%10.22 مليار USD0.44%98.31 US$+0.92%
Schwab U.S. Small-Cap ETFSCHA21 مليون0.10%21.82 مليار USD0.03%32.79 US$+0.40%
iShares Russell 2000 Growth ETFIWO17.79 مليون0.13%13.92 مليار USD0.24%356.78 US$+0.94%
iShares U.S. Pharmaceuticals ETFIHE13.81 مليون0.90%1.55 مليار USD0.37%100.09 US$+1.24%
Vanguard Russell 2000 ETFVTWO12.31 مليون0.07%18 مليار USD0.06%112.66 US$+0.50%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFJPMorgan Active Growth ETFJGROSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEVanguard Russell 2000 ETFVTWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
